Elan Announces First European Commission Approval of Injectable Treatment Using NanoCrystal® Technology - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Elan Announces First European Commission Approval of Injectable Treatment Using NanoCrystal® Technology

Elan Drug Technologies (EDT), the leading drug delivery unit of Elan Corporation, has announced that the first injectable product using EDT’s NanoCrystal® technology has been approved by the European Commission. XEPLION®, Janssen-Cilag International’s long-acting injectable treatment for patients with schizophrenia which uses EDT’s NanoCrystal® technology, was approved by the European Commission yesterday.

“The European approval of XEPLION® is an important milestone for our NanoCrystal® technology as it marks the first long-acting injectable product approved by the European regulatory authorities using the technology,” said Shane Cooke, executive vice president and chief financial officer of Elan and Head of EDT. “The versatility of our NanoCrystal® technology enabled the development of a long-acting injectable antipsychotic which is designed to help patients maintain continual treatment, reduce the likelihood of relapse and thereby potentially improve their overall quality of life.”

On 9 March 2011, Janssen-Cilag International, one of the Janssen Pharmaceutical Companies, announced the approval of XEPLION®, a once monthly atypical antipsychotic injection, by the European Commission. XEPLION® is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, XEPLION® may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

EDT’s NanoCrystal® technology enables the formulation of poorly water soluble compounds for all routes of administration. The technology allows for a ready-to-use, one-month duration, intramuscular injection formulation of paliperidone palmitate which can be administered by healthcare professionals. The intramuscular injection is administered using a small bore needle and small volume syringe, thereby negating the need for a power injector. By applying the NanoCrystal® technology to paliperidone palmitate, healthcare professionals will be able to provide patients with consistent medication coverage for one month, potentially allowing them to improve compliance for patients with schizophrenia.

NanoCrystal® technology is a proprietary technology developed by EDT through Elan Pharma International Limited and other Elan affiliates. XEPLION® is the fourth licensed product using Elan’s NanoCrystal® technology that has been approved by the EMA.

More About This Company